Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Webcast

Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference


Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand beginning on Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (www.cyclotherapeutics.com). The webcast replay will be archived for 90 days following the event.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company's Trappsol® Cyclotm, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclotm intravenously in Alzheimer's Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer's Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclotm are in development. For additional information, visit the Company's website: www.cyclotherapeutics.com.


These press releases may also interest you

at 12:45
Sogolytics Study Examines Patient Experience Gaps in Telehealth Adoption
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients. "It's critical for providers...

at 12:39
Interfuse Adds New Features to its Knowledge Base
In an effort to provide the best service possible, enterprise developer Interfuse, has added several important improvements to its Knowledge Base application. Within this update, new pages accessible in the Knowledge Base include Recently Added,...

at 12:16
Amae Health, Innovative Treatment Provider for Severe Mental Illness, Announces Closing of Oversubscribed $15 Million Series A Funding Round
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...

at 12:05
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadranttm for Supply Chain Planning Solutions
Kinaxis® Inc. , a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadranttm for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis...

at 12:05
Radiance Biopharma to Present at LSX World Congress 2024
Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that...

at 12:00
Jill Priya Keshyap Tapped as Guild of Guardians Executive Producer, Bringing Experience from Animoca Brands, Voodoo.io, Facebook, and more
Today, Immutable Games, a global leader in web3 game development and publishing, announced the hiring of Priya Keshyap as Executive Producer for Guild of Guardians, the epic fantasy RPG which comes to mobile on May 15. Keshyap draws on more than a...

More news about Science and technology...


News published on and distributed by: